Woodline Partners LP Seagen Inc. Transaction History

Woodline Partners LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $3.85 Million - $4.35 Million	20,106 Added 20.01%	120,606 $25.6 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $5.66 Million - $6.22 Million	30,150 Added 42.86%	100,500 $19.3 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $22.9 Million - $36.5 Million	-179,564 Reduced 71.85%	70,350 $14.2 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $29.3 Million - $34.8 Million	249,914 New	249,914 $32.1 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $128 Million - $211 Million	-1,174,073 Reduced 83.4%	233,620 $41.3 Million

Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $88.5 Million - $117 Million	739,689 Added 110.73%	1,407,693 $203 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $12.9 Million - $17.2 Million	90,300 Added 15.63%	668,004 $103 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $6,980 - $8,321	49 Added 0.01%	577,704 $98.1 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $71.2 Million - $84.9 Million	526,768 Added 1035.17%	577,655 $91.2 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $149,885 - $207,972	1,090 Added 2.19%	50,887 $7.07 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $8.2 Million - $10.6 Million	49,797 New	49,797 $8.72 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.